{"id":"NCT01242527","sponsor":"AstraZeneca","briefTitle":"Epanova® for Lowering Very High Triglycerides","officialTitle":"Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-01","primaryCompletion":"2012-03","completion":"2012-04","firstPosted":"2010-11-17","resultsPosted":"2013-09-06","lastUpdate":"2016-08-04"},"enrollment":399,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Severe Hypertriglyceridemia"],"interventions":[{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"omefas","otherNames":[]},{"type":"DRUG","name":"omefas","otherNames":[]},{"type":"DRUG","name":"omefas","otherNames":[]}],"arms":[{"label":"placebo","type":"PLACEBO_COMPARATOR"},{"label":"Epanova 2 g","type":"EXPERIMENTAL"},{"label":"Epanova 3 g","type":"EXPERIMENTAL"},{"label":"Epanova 4 g","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.","primaryOutcome":{"measure":"Fasting Serum Triglycerides","timeFrame":"12 weeks","effectByArm":[{"arm":"Olive Oil (Placebo)","deltaMin":-4.26,"sd":null},{"arm":"Epanova 2 g","deltaMin":-25.94,"sd":null},{"arm":"Epanova 3 g","deltaMin":-25.46,"sd":null},{"arm":"Epanova 4 g","deltaMin":-30.86,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.005"},{"comp":"OG000 vs OG002","p":"0.007"},{"comp":"OG000 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":21},"locations":{"siteCount":68,"countries":["United States","Denmark","Hungary","India","Netherlands","Russia","Ukraine"]},"refs":{"pmids":["24528690"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":99},"commonTop":["Diarrhoea","Nausea","Nasopharyngitis"]}}